---
title: Continuation versus Interruption of Oral Anticoagulation during TAVI
date: '2024-08-31'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39216096/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240901181504&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: In patients undergoing TAVI with a concomitant indication
  for oral anticoagulation, periprocedural continuation was not noninferior to interruption
  of oral anticoagulation during TAVI with respect to the incidence of a composite
  of death from cardiovascular causes, stroke, myocardial infarction, major vascular
  complications, or major bleeding at 30 days. (Funded by the Netherlands Organization
  for Health Research and Development and the St. Antonius Research Fund; POPular
  PAUSE ...'
disable_comments: true
---
CONCLUSIONS: In patients undergoing TAVI with a concomitant indication for oral anticoagulation, periprocedural continuation was not noninferior to interruption of oral anticoagulation during TAVI with respect to the incidence of a composite of death from cardiovascular causes, stroke, myocardial infarction, major vascular complications, or major bleeding at 30 days. (Funded by the Netherlands Organization for Health Research and Development and the St. Antonius Research Fund; POPular PAUSE ...